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Genistein aglycone, one of the soy isoﬂavones, has been reported to be beneﬁcial in
the treatment of menopausal vasomotor symptoms, osteoporosis, and cardiovascular dis-
eases, as well as in a variety of cancers. However, issues of potential harm on thyroid
function resulting from soy isoﬂavones consumption have been raised. Much of the evi-
dence for the goitrogenic effects of isoﬂavones is derived from experimental in vitro and
in vivo studies. Goitrogenic effects were also noted in infants fed non-iodine-fortiﬁed, soy-
based formula, a problem that was easily solved with iodine fortiﬁcation. Recent studies
suggest that genistein shows a good proﬁle of safety on the thyroid although deﬁnitive
conclusions have not reached. The aim of this brief review is to summarize and better
clarify the effects of genistein on human thyroid health.
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Genistein (4′,5,7-trihydroxyﬂavone) is a phytoestrogen belonging
to the class of soy isoﬂavones, a sub-class of ﬂavonoids that have
received great attention for their potential on human health bene-
ﬁts. Many epidemiological studies suggest that high dietary intake
of soy is associated with lower incidence rates of certain forms of
cancers (Setchell, 1998; Messina andMessina, 2010). Indeed,Asian
women, whose diet is rich in isoﬂavones, have a low incidence
of breast cancer as well as of other hormone-associated prob-
lems, such as osteoporosis and menopausal symptoms (Somekawa
et al., 2001: Messina et al., 2004). Of the soy isoﬂavones, genis-
tein ranks ﬁrst in terms of mass of experimental and clinical
studies performed. Genistein aglycone is an isoﬂavone found
at low concentrations in soybeans but at high concentrations
in certain soy-derived food. In contrast, genistin, the gluco-
side form of the aglycone genistein, is much more abundant in
the unprocessed soybean. Structurally, genistein closely resem-
bles 17β-estradiol (Figure 1), and indeed it binds to the estrogen
receptors (ERs), the stronger afﬁnity being for the ERβ isoform
(Kuiper et al., 1998). Acting as a natural selective ER modula-
tor, genistein exerts its estrogen agonist or antagonist action in a
tissue- and dose-dependent manner (Setchell, 2001). Moreover,
several in vitro and in vivo studies show that genistein aglycone
has antineoplastic effects which stem from multiple actions: (a)
modulation of cell growth and proliferation throughout tyro-
sine kinases and topoisomerase II inhibition, (b) stimulation of
the immune system, (c) antiangiogenic effects, and (d) potent
antioxidant capacity (Polkowski and Mazurek, 2000). Addition-
ally, the anticancer property of genistein may be likely due
to DNA methylation and/or chromatin modiﬁcation (Li and
Tollefsbol, 2010).
Recently, clinical trials have been conducted to evaluate
the beneﬁt of genistein aglycone as a cure for menopausal
vasomotor symptoms, osteoporosis, and cardiovascular disease.
Speciﬁcally, administration of 54 mg/day genistein aglycone to
postmenopausal women with low bone mass results in posi-
tive (beneﬁcial) changes in vasomotor symptoms, bone mineral
density and markers of bone turnover, and some predictors of car-
diovascular risk without harmful estrogenic activity in the breast
and uterus (Atteritano et al., 2007; Marini et al., 2007, 2008, 2010;
D’Anna et al., 2009). In those studies, administration of pure
genistein avoided possible interferences by other isoﬂavones and
resulted in documented and stable increases of the isoﬂavone’s
serum level. The promising safety proﬁle of genistein aglycone
may be a direct consequence of its greater afﬁnity for the ERβ,
which is particularly abundant in both the trabecular bone dur-
ing the mineralization phase and the artery endothelial tissue,
than ERα, which is more represented in the reproductive tissues
(Nilsson and Gustafsson, 2011).
It is known that estrogens exert several effects on thyroid fol-
licular cells, in that they modulate their cell cycle progression,
proliferation, and function, thus potentially contributing to the
pathogenesis of thyroidhyperplasia and even thyroid cancer. These
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FIGURE 1 | Chemical structure of genistein and estradiol.
effects are mediated by the binding to ERs as well as through
distinct non-genomicmolecular pathways (Ben-Rafael et al., 1987;
Santin and Furlanetto, 2011). However, the expression of ERs in
normal and neoplastic human thyroid tissues remains controver-
sial probably because of inter-study differences in the methods
used to quantify their expression. Another controversy of major
concern is the different action of ERα and ERβ in neoplastic
thyroid (Chen et al., 2008; Santin and Furlanetto, 2011).
Thyroid hormones regulate several metabolic processes and
are crucial for normal growth, development, and maturation of
the central nervous system, the cardiovascular system, and the
skeleton in mammals. Decreased thyroid hormones synthesis and
action results in impaired neuro-cognitive function and increased
risk for cardiovascular diseases (Biondi and Cooper, 2008), thus
impacting negatively on human health.
EXPERIMENTAL STUDIES
Studies on the relationship between soybean intake and thyroid
function have started about 80 years ago (Divi et al., 1997; Fitz-
patrick, 2000; Doerge and Chang, 2002; Doerge and Sheehan,
2002); they suggest that consumption of soy and, speciﬁcally
soy isoﬂavones as genistein, is goitrogenic and alters thyroid
function.
The goitrogenic effects of genistein seem to derive from a direct
interaction of this isoﬂavonewith key pathways involved in thyroid
hormones synthesis, metabolism, and thyroid hormone trans-
port proteins (Radovic´ et al., 2006). In vitro and in vivo studies
showed that genistein is a potent inhibitor of thyroid peroxi-
dase (TPO), a key enzyme in thyroid hormone synthesis (Divi
and Doerge, 1996; Divi et al., 1997; Chang and Doerge, 2000;
Doerge and Sheehan, 2002). Indeed, TPO catalyzes the iodina-
tion of thyroglobulin and oxidative coupling of diiodothyronine
resulting in the thyroid hormone formation. Thus, inhibition
of TPO leads to a reduction of thyroid hormones levels, with a
subsequent increment of TSH release, that, in turn, provides a
strong growth stimulus to the thyroid gland. Moreover, genis-
tein also affects the metabolism of thyroid hormones and iodide
re-utilization by inhibition of sulfotransferase enzymes (Ebmeier
and Anderson, 2004).
Divi et al. (1997) demonstrated that the TPO-catalyzed iodi-
nation of tyrosine inhibited by genistein is dose-dependent; this
effect reverses when sufﬁcient amounts of iodide are added to
incubationmixtures. Similar inhibitionwas observed in ratmicro-
somal TPO and in rats feeding a diet fortiﬁed with different
doses of genistein, but no changes were observed in blood sera
levels of thyroid hormone or TSH (Chang and Doerge, 2000).
Genistein is also known as a potent, dose-dependent, inhibitor
of tyrosine kinase (Ravindranath et al., 2004), as well as thyroid
hormone deiodination mediated by 5′-iodothyronine deiodinase
(Mori et al., 1996; White et al., 2004).
Usingpreparations of liver enzymes, Ferreira et al. (2002) found
that ﬂavonoids other than genistein inhibited 5′-iodothyronine
deiodinase. Indeed, in vivo experiments with the synthetic
ﬂavonoid EMD 21388 (Schröder-van der Elst et al., 1991), which
inhibits thyroid hormone binding to plasma transthyretin, show
a reduction of T3 content in tissues that express type II 5′-
iodothyronine deiodinase.
More recently, Sosic´-Jurjevic´ et al. (2010) showed that a sub-
cutaneous injection of 10 mg/kg of genistein or daidzein can
disturb the pituitary-thyroid axis, causing hypothyroidism in
orchidectomized middle-aged rats.
However, overall in vitro and in vivo data from animal stud-
ies are not easily to compare with data from human studies, as
demonstrated by a recent paper (Setchell et al., 2011).
HUMAN STUDIES
In humans, early studies showed that feeding infants with soy
milk caused goiter in those with inadequate iodine intake even
if this effect was reverted by iodine supplementation (Chorazy
et al., 1995; Jabbar et al., 1997). Moreover, of 530 children aged
6–15 years living in iodine-deﬁcient areas of India and consuming
large amounts of ﬂavonoids, almost all were goitrous (Brahmb-
hatt et al., 2000). This enormous rate of thyroid enlargement
led the authors to conclude that goiter was due to the com-
bined effect of iodine deﬁciency and ﬂavonoid excess in their diet
(Brahmbhatt et al., 2000).
A more recent human trial reports the effects of short-term soy
consumption on thyroid parameters in relation with isoﬂavone
levels in male and female healthy subjects (Hampl et al., 2008).
After 7 days of soy consumption, levels of both genistein and
daidzein were increased. The statistically signiﬁcant relationships
found at the end of soy consumption were: (i) between basal levels
of daidzein and thyrotropin, (ii) between daidzein and antithy-
roglobulin in males, and (iii) between daidzein and free thyroxine
in females. Genistein lacked any correlation with the above thy-
roid parameters. These results agree with a previous research
in 268 children (Milerová et al., 2006). The authors investigated
whether serum levels of genistein and daidzein were correlated
with thyroid hormone function. This study showed only a modest
association between isoﬂavones serum levels and parameters of
thyroid function, such as free thyroxine, thyroglobulin antibodies,
and thyroid volume.
It is well known that thyroid diseases are most common in
women, especially during perimenopause and menopause, per-
haps as consequence of an altered balance between estrogens
and progesterone. Accordingly, the effects of genistein on thyroid
function were also analyzed in postmenopausal women. Results
from a 3-month study in postmenopausal women consuming an
isoﬂavone-rich diet (containing 58% of total genistein) showed
no signiﬁcant effect of isoﬂavones on serum levels of thyroid
hormones (Duncan et al., 1999).
Bruce et al. (2003) investigated thyroid function in 38
iodine-repleted postmenopausal women at baseline and after 90
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and 180 days following supplementation with 90 mg (aglycone
weight) of total isoﬂavones/day. Thyroid parameters did not differ
between the placebo and the treatment arm.
In a 16-week duration study, 77 postmenopausal women were
randomized to receive cow’s milk and a placebo supplement, soy
milk and placebo supplement, or cow’s milk and isoﬂavone sup-
plement (Ryan-Borchers et al., 2008). The results of this study are
congruent with those of Bruce et al. (2003) and provide evidence
that the levels of isoﬂavone intake do not adversely affect thy-
roid function, as indicated by serum TSH levels that remained
within the normal range following the intervention period in all
women; cognitive functioning in healthy postmenopausal women
was also unaffected. Amore recent clinical trial in postmenopausal
women evaluated the effects of 3-year administration of pure
genistein aglycone (54 mg/day) on thyroid-related markers (Bitto
et al., 2010). Speciﬁcally, changes in thyroid hormone receptors
expression, serum levels of thyroid hormones, and thyroid anti-
bodies were assessed. The results showed that daily consumption
of genistein aglycone did not modify circulating FT4, FT3, and
TSH levels or thyroid antibodies. Furthermore, genistein aglycone
administration over 3 years did not affect the expression of thyroid
hormone receptors in peripheral blood mononuclear cells, thus
conﬁrming that genistein appears not to alter thyroid function in
postmenopausal women.
A 12-week duration randomized, double-blind and placebo-
controlled trial in 43 oophorectomized Indian women, evaluated
the effect of 75mg/day soy isoﬂavones (genistein and genistin 25%;
daidzein and daidzin 15%) on serum levels FT3, FT4, TSH, TBG,
and anti-TPO antibodies (Mittal et al., 2011). The only variation
found was a modest decrease in serum FT3.
Finally, a recent study in men with localized prostate cancer
addressed the safety of genistein in the male gender (Lazarevic
et al., 2011). Genistein was administered at the dose of 30 mg/day
for 3–6 weeks prior to prostatectomy, and thyroid hormones lev-
els were measured as secondary outcome. Serum levels of thyroid
hormones remained statistically unchanged.
CONCLUSION
Overall, there is a scarcity of information about the effect of
pure isoﬂavones, such as genistein, on thyroid safety in humans.
Results of intervention trials are not easily comparable because
the researchers have used (i) mixed isoﬂavones or isoﬂavone and
protein mixtures with different dosage regimens, soy foods or sup-
plements as the active treatment; (ii) the quality and amount of
genistein varied widely in all of these previous studies; and (iii)
the trials were of different duration. Although the overall evidence
suggests that isoﬂavone genistein does not affect adversely thyroid
function in euthyroid, iodine-replete individuals, further studies
are warranted to better deﬁne the relationship between genistein
and thyroid.
Infants and women deserve particular attention in order to
assess the safety of genistein and/or other isoﬂavones on thy-
roid function, also considering that thyroid disorders are age- and
gender-related.
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